
BiotechTV - News
From London: iOnctura is developing its allosteric PI3Kδ for uveal melanoma - an indication that has seen progress but still has much unmet need
12 min•19 mars 2026
Om avsnittet
From Syncona's Capital Markets Day, Founder and CEO Catherine Pickering walks us through the science of roginolisib and describes the current landscape for uveal melanoma. She discusses her phase 2, which is approaching a key readout.
Fler avsnitt
Visa alla avsnitt av BiotechTV - NewsBiotechTV - News med BiotechTV finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.